Funding and Investments

Apr 20, 2018
By BioPharm International Editors
LNC Therapeutics has appointed a new CEO and is strengthening its R&D for gut microbiome-based drugs.
Apr 12, 2018
By BioPharm International Editors
The new facility, to be built in Toronto, Canada, will significantly increase capacity for pediatric and booster vaccines.
Feb 22, 2018
By BioPharm International Editors
The company aims to add the additional analytical services in the European Union throughout 2018.
Feb 12, 2018
By BioPharm International Editors
The companies have been awarded a collaborative grant of £1.9 million (US$2.6 million) from Innovate UK.
Feb 06, 2018
By BioPharm International Editors
Amgen plans to invest approximately $300 million in a new biomanufacturing plant in the United States.
Feb 01, 2018
BioPharm International
Single-use technologies are starting to gain ground as capacity needs change, but industrywide adoption remains low.
Jan 11, 2018
By BioPharm International Editors
Athenex is moving forward with the construction of a new 320,000-square-foot pharmaceutical manufacturing facility in Dunkirk, NY, and has hired the German engineering firm, M+W, to design and construct the facility.
Jan 11, 2018
By BioPharm International Editors
A Takeda and Denali collaboration includes three named programs for treating Alzheimer’s disease and other neurodegenerative diseases, using Denali’s antibody transport vehicle (ATV) technology to enhance blood-brain barrier penetration.
Jan 11, 2018
By BioPharm International Editors
The company will use funding from the Bill & Melinda Gates Foundation to develop a new production method for artemisinin, a therapeutic used to treat malaria.
Jan 05, 2018
By BioPharm International Editors
The companies aim to discover and develop locked nucleic acid oligonucleotides as orally available therapies for treating inflammatory bowel diseases.
native1_300x100
lorem ipsum